Ali Faraz 4

What Happened
Ali Faraz, CEO of Tenaya Therapeutics (TNYA), reported a sale of 3,390 shares on 2026-05-18 at $0.79 per share, generating proceeds of $2,690. The filing indicates the sale was to cover tax withholding obligations tied to the vesting of restricted stock units (RSUs).

Key Details

• Transaction date: 2026-05-18; Filing date (Form 4): 2026-05-19 (appears timely).
• Transaction type/code: Sale (S) — open market or private sale; footnote F1: sale to cover tax withholding for vested RSUs awarded 2025-02-06.
• Price and proceeds: 3,390 shares × $0.79 = $2,690 (disposed).
• Footnote F2: Reporting person is scheduled to receive 321,581 shares upon vesting of RSUs (i.e., unvested awards that will convert to shares).
• No indication this was part of a 10b5-1 plan; transaction is described as tax-withholding related.

Context
This was a routine sale to satisfy tax withholding on vested RSUs rather than a discretionary portfolio sale. Such withholding sales are common and typically not read as a directional signal about the insider’s view of the company.